Citadel Advisors’s Genetic Technologies Ltd. GENE Stock Holding History

Citadel Advisors’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-240	Closed	-$1.4K	–	15479
2023 Q1	$1.4K	Buy	+240	New	+$1.41K	﹤0.01%	14307
2022 Q2	–	Sell	-6,120	Closed	-$60K	–	14434
2022 Q1	$60K	Sell	6,120 -2,180	-26%	-$21.2K	﹤0.01%	12687
2021 Q4	$78K	Buy	8,300 +4,000	+93%	+$51.3K	﹤0.01%	12967
2021 Q3	$66K	Sell	4,300 -1,620	-27%	-$27.8K	﹤0.01%	13205
2021 Q2	$126K	Sell	5,920 -2,640	-31%	-$53.2K	﹤0.01%	12699
2021 Q1	$178K	Buy	8,560 +1,480	+21%	+$33.9K	﹤0.01%	11841
2020 Q4	$127K	Buy	+7,080	New	+$117K	﹤0.01%	10058

Other funds holding GENE

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Citadel Advisors's GENE Position: Q4 2024 in Review

Citadel Advisors sold out of Genetic Technologies Ltd. (GENE) in Q4 2024, closing a stake of 682 shares — an estimated $510 sold.

Citadel Advisors first reported a position in GENE in Q1 2014 and held it in 24 quarters. The position peaked at $438K in Q1 2021. 1 fund tracked by Wall St. Rank holds GENE as of Q4 2024.

Citadel Advisors reported no remaining Genetic Technologies Ltd. position as of Q4 2024 after selling out during the quarter.
Citadel Advisors sold 682 Genetic Technologies Ltd. shares in Q4 2024, an estimated $510.
Citadel Advisors first reported a position in Genetic Technologies Ltd. in Q1 2014 and held it in 24 quarters.
Citadel Advisors's Genetic Technologies Ltd. position peaked at $438K in Q1 2021.
1 fund tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.